Dyne Therapeutics (NASDAQ:DYN) Given New $11.00 Price Target at Oppenheimer

Dyne Therapeutics (NASDAQ:DYN) had its target price dropped by research analysts at Oppenheimer from $13.00 to $11.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “market perform” rating on the stock. Oppenheimer’s price objective would suggest a potential downside of 41.76% from the stock’s previous close.

Several other brokerages have also commented on DYN. HC Wainwright boosted their target price on shares of Dyne Therapeutics from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Evercore ISI reissued an “outperform” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research note on Thursday, November 6th. Chardan Capital decreased their target price on shares of Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, July 29th. Raymond James Financial raised Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $31.00 to $35.00 in a research note on Monday, August 25th. Finally, JPMorgan Chase & Co. dropped their target price on Dyne Therapeutics from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, July 15th. Four research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.40.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock traded down $0.78 during mid-day trading on Wednesday, reaching $18.89. 370,417 shares of the company were exchanged, compared to its average volume of 2,640,617. The firm’s 50-day simple moving average is $15.88 and its two-hundred day simple moving average is $12.90. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $35.68. The firm has a market cap of $2.70 billion, a PE ratio of -4.90 and a beta of 1.15. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.05. Equities analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox sold 2,640 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $13.41, for a total value of $35,402.40. Following the sale, the chief executive officer directly owned 199,539 shares in the company, valued at $2,675,817.99. This trade represents a 1.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 14.14% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd raised its stake in Dyne Therapeutics by 54.5% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 124,628 shares of the company’s stock valued at $1,186,000 after purchasing an additional 43,963 shares during the period. Graham Capital Management L.P. acquired a new stake in shares of Dyne Therapeutics in the 1st quarter valued at $651,000. Voleon Capital Management LP bought a new stake in shares of Dyne Therapeutics during the 1st quarter worth about $624,000. Bryce Point Capital LLC bought a new stake in shares of Dyne Therapeutics during the 2nd quarter worth $115,000. Finally, Swiss National Bank boosted its holdings in Dyne Therapeutics by 8.9% during the first quarter. Swiss National Bank now owns 118,300 shares of the company’s stock valued at $1,237,000 after acquiring an additional 9,700 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.